Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 19, 2017

Primary Completion Date

April 12, 2021

Study Completion Date

April 20, 2021

Conditions
Type 1 Diabetes
Interventions
DRUG

Ergocalciferol

Each subject on the experimental arm will receive one capsule of ergocalciferol per week for 2 months; and then once every 2 weeks for 10 months

OTHER

Placebo

Each subject on the placebo arm will receive one capsule of placebo per week for 2 months; and then once every 2 weeks for 10 months

Trial Locations (1)

01655

University of Massachusetts Medical School, Worcester

All Listed Sponsors
collaborator

University of Massachusetts, Worcester

OTHER

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Benjamin U. Nwosu, MD

OTHER

NCT03046927 - Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes | Biotech Hunter | Biotech Hunter